company background image
6634 logo

Sinew Pharma TPEX:6634 Stock Report

Last Price

NT$50.10

Market Cap

NT$3.6b

7D

-5.5%

1Y

-23.0%

Updated

17 Mar, 2025

Data

Company Financials

6634 Stock Overview

A biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. More details

6634 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Sinew Pharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sinew Pharma
Historical stock prices
Current Share PriceNT$50.10
52 Week HighNT$80.90
52 Week LowNT$43.85
Beta0.98
1 Month Change-7.05%
3 Month Change6.60%
1 Year Change-23.04%
3 Year Change-42.21%
5 Year Change174.97%
Change since IPO0.60%

Recent News & Updates

Recent updates

Companies Like Sinew Pharma (GTSM:6634) Can Afford To Invest In Growth

Mar 11
Companies Like Sinew Pharma (GTSM:6634) Can Afford To Invest In Growth

Sinew Pharma (GTSM:6634) Is In A Strong Position To Grow Its Business

Nov 25
Sinew Pharma (GTSM:6634) Is In A Strong Position To Grow Its Business

Shareholder Returns

6634TW PharmaceuticalsTW Market
7D-5.5%-3.0%-2.7%
1Y-23.0%5.8%10.5%

Return vs Industry: 6634 underperformed the TW Pharmaceuticals industry which returned 5.8% over the past year.

Return vs Market: 6634 underperformed the TW Market which returned 10.5% over the past year.

Price Volatility

Is 6634's price volatile compared to industry and market?
6634 volatility
6634 Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement3.6%
Market Average Movement4.3%
10% most volatile stocks in TW Market7.8%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6634 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 6634's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201451Kai-Min Chuwww.sinewpharma.com

Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630 drug, for which is in Phase II clinical trial. It is also developing SNP-810 is in phase II clinical trial for use in Pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States.

Sinew Pharma Inc. Fundamentals Summary

How do Sinew Pharma's earnings and revenue compare to its market cap?
6634 fundamental statistics
Market capNT$3.57b
Earnings (TTM)-NT$150.37m
Revenue (TTM)n/a

0.0x

P/S Ratio

-23.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6634 income statement (TTM)
RevenueNT$0
Cost of RevenueNT$0
Gross ProfitNT$0
Other ExpensesNT$150.37m
Earnings-NT$150.37m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.11
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 6634 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 21:51
End of Day Share Price 2025/03/17 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sinew Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.